Angion Biomedica
Latest round
- Series C
Last raised
- Jun 2020
Total raised
- $6.7M
Investors
- 1
About Angion Biomedica
Founded in 1998 and based in New York, US, Angion Biomedica Corp. operates as a biotechnology company that develops small molecule targeting therapeutics to treat patients with acute kidney and lung injury related to transplantation COVID-19 related pneumonia. This includes an IPO (Initial Public Offering) prospectus dated March 2014 that was withdrawn in October of the same year. In February 2021, Angion Biomedica Corp. The company's medical R&D team focuses on discovering, developing, and commercializing small molecule therapeutics to treat acute organ injuries and chronic fibrotic diseases by understanding the HGF (hepatocyte growth factor) and fibrotic pathways involved in tissue repair and organ recovery. The product pipeline includes ANG-3777, ANG-3070, ROCK2 Inhibitor, and CYP11B2 Inhibitor. The company plans to list on the Nasdaq global select market under the ticker symbol ANGN.
Who invested in Angion Biomedica
1 investor across 1 round
See all investors in Angion Biomedica
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series C
Jun 12, 2020
Amount
$6.7M
Investors
Questions about Angion Biomedica
Who invested in Angion Biomedica?
Angion Biomedica has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Angion Biomedica raised?
Angion Biomedica has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Angion Biomedica last raise money?
Angion Biomedica's most recent round on record is a Series C, in Jun 2020.
What does Angion Biomedica do?
Founded in 1998 and based in New York, US, Angion Biomedica Corp.
Where is Angion Biomedica headquartered?
Angion Biomedica is headquartered in San Francisco, US.
Which VCs invest in companies like Angion Biomedica?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Angion Biomedica's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Angion Biomedica? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.